Literature DB >> 23683993

Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.

Seetal Dodd1, Michael Berk, Katarina Kelin, Michele Mancini, Alexander Schacht.   

Abstract

Mental illness has been observed to follow a neuroprogressive course, commencing with prodrome, then onset, recurrence and finally chronic illness. In bipolar disorder and schizophrenia responsiveness to treatment mirrors these stages of illness progression, with greater response to treatment in the earlier stages of illness and greater treatment resistance in chronic late stage illness. Using data from 5627 participants in 15 controlled trials of duloxetine, comparator arm (paroxetine, venlafaxine, escitalopram) or placebo for the treatment of an acute depressive episode, the relationship between treatment response and number of previous depressive episodes was determined. Data was dichotomised for comparisons between participants who had >3 previous episodes (n=1697) or ≤3 previous episodes (n=3930), and additionally for no previous episodes (n=1381) or at least one previous episode (n=4246). Analyses were conducted by study arm for each clinical trial, and results were then pooled. There was no significant difference between treatment response and number of previous depressive episodes. This unexpected finding suggests that treatments to reduce symptoms of depression during acute illness do not lose efficacy for patients with a longer history of illness.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressant; Depression; Meta-analysis; Staging; Treatment

Mesh:

Substances:

Year:  2013        PMID: 23683993     DOI: 10.1016/j.jad.2013.04.016

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.

Authors:  Bruno R Barros; Alexander Schacht; Michael Happich; Foula Televantou; Lovisa Berggren; Daniel J Walker; Hector J Dueñas
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-02

Review 2.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

3.  The clinical relevance of qualitatively distinct subtypes of depression.

Authors:  Lars Vedel Kessing; Jens Drachmann Bukh
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

4.  Preventive psychiatry: a blueprint for improving the mental health of young people.

Authors:  Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis
Journal:  World Psychiatry       Date:  2021-06       Impact factor: 79.683

5.  Between wellness, relapse, and remission: Stages of illness in anorexia nervosa.

Authors:  Joanna E Steinglass; Deborah R Glasofer; Maya Dalack; Evelyn Attia
Journal:  Int J Eat Disord       Date:  2020-02-07       Impact factor: 5.791

6.  Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Authors:  Stuart A Montgomery; Carl P Gommoll; Changzheng Chen; William M Greenberg
Journal:  CNS Spectr       Date:  2014-06-05       Impact factor: 3.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.